TD Cowen analyst Daniel Brennan reiterated a Buy rating on Danaher (DHR – Research Report) today and set a price target of $248.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Daniel Brennan’s rating is based on several compelling factors that suggest a positive outlook for Danaher. The company demonstrated a strong performance in the first quarter, which was particularly notable given the weaker stock performance of Danaher and its peers year-to-date. The management’s confident outlook, especially in navigating potential tariff impacts and macroeconomic challenges, further supports the Buy rating. They have outlined a robust plan to mitigate these pressures, including cost-cutting measures and strategic adjustments in manufacturing and supply chain operations.
Moreover, Danaher’s management has expressed optimism about future organic growth, particularly by 2026, as current headwinds like China’s volume-based procurement and life sciences competition issues are expected to diminish. The earnings per share guidance for 2025 includes a healthy cushion, potentially enhanced by favorable foreign exchange rates and additional cost reductions. These strategic initiatives and the company’s ability to adapt to changing conditions underscore its strong positioning, justifying the Buy rating and the increase in the price target to $248.
According to TipRanks, Brennan is a 4-star analyst with an average return of 6.3% and a 38.02% success rate. Brennan covers the Healthcare sector, focusing on stocks such as Illumina, Danaher, and Waters.